Tonix Pharmaceut Stock Price, News & Analysis

Tonix Pharmaceuticals will deliver an oral presentation and present two posters at the ASCP Annual Meeting from May 28-31, 2024. The oral presentation will cover findings from Phase 3 studies of Tonmya (TNX-102 SL) for fibromyalgia, which met its primary endpoint, reducing daily pain significantly compared to a placebo. Posters will highlight TNX-102 SL's Phase 2 study in Long COVID and an upcoming trial on acute stress disorder. Tonix plans to submit an NDA to the FDA in the second half of 2024 for Tonmya. The presentations will be available on Tonix's website after the conference.

Tonix Pharmaceuticals has announced key findings from the initial phase of EVERSANA's market analysis for Tonmya, a potential first-line, non-opioid treatment for fibromyalgia. The report reveals high interest in Tonmya among primary care physicians and significant dissatisfaction with current FDA-approved drugs. Opioids are frequently prescribed despite their risks. Tonmya has shown promising results in two Phase 3 trials, reducing pain and improving sleep and overall symptoms. Tonix aims to submit an NDA to the FDA in the second half of 2024, with an anticipated launch in 2025.

Tonix Pharmaceuticals (Nasdaq: TNXP) announced that CEO Seth Lederman will participate virtually in a fireside chat at the A.G.P. Healthcare Company Showcase on May 21, 2024, at 9:00 a.m. ET.

The presentation will be live webcast and available for replay on the Tonix website.

Tonix is a biopharmaceutical company focused on developing therapeutics for CNS disorders, including submitting a New Drug Application (NDA) for Tonmya in the second half of 2024.

Other key products in their portfolio include TNX-1300 for cocaine intoxication and TNX-1500 for organ transplant rejection and autoimmune diseases. Tonix also markets Zembrace SymTouch and Tosymra for acute migraine treatment.

Tonix Pharmaceuticals (Nasdaq: TNXP) announced its Q1 2024 financial results and operational highlights. The company is preparing to submit a New Drug Application (NDA) for Tonmya™ for fibromyalgia by H2 2024, with FDA approval expected in H2 2025. Tonmya, a non-opioid analgesic, has shown efficacy in Phase 3 trials without common side effects. Net revenue for Q1 2024 was $2.5 million, with a net loss of $14.9 million. Other key programs include treatments for PTSD, Long COVID, cocaine intoxication, and rare diseases. Cash and equivalents were $7.0 million as of March 31, 2024.